As of Nov 19, 2026, 1 of 1 active firms rate NXTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NXTC EPS & revenue forecast
EPS · NEXT QUARTER
$-2.23
Range $-2.23 – $-2.23 · 1 analysts · +19% YoY
Next period, 1 analysts expect NextCure Inc to earn $-2.23 a share (range $-2.23 – $-2.23), versus $-1.87 a year earlier. Full-year consensus is $-6.34, growing to $-5.89 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering NextCure Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NXTC.
#1
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$15.00+117.9% to target
Overall win rate
29%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$20.00+190.5% to target
Overall win rate
24%
+ Follow
#3
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$18.00+161.4% to target
Coverage
—
+ Follow
#4
CL
Christopher Liu
Lucid Capital
Buy
$25.00+263.1% to target
Coverage
—
+ Follow
#5
CL
Christopher Liu
LUCID CAPITAL MARKETS
Buy
$25.00+263.1% to target
Coverage
—
+ Follow
NXTC stock forecast FAQ
What is NXTC's average 12-month price target?+
The 1 active firms with a live target average $25.00 for NextCure Inc over the next 12 months, ranging from a $25.00 high to a $25.00 low, as of Nov 19, 2026.
Is NXTC stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover NXTC?+
1 active firms have a recognized rating on NextCure Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NXTC?+
Among analysts who currently cover NXTC, Edward Tenthoff of Piper Sandler has the strongest overall Quantellect track record (Rank #460). Their current call is Buy with a $15.00 target.
What is NextCure Inc's projected EPS for next quarter?+
The consensus estimate is $-2.23 per share (range $-2.23 – $-2.23) across 1 analysts. Full-year EPS is projected at $-6.34, rising to $-5.89 the following year.
How much revenue is NextCure Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NXTC lately?+
As of Nov 19, 2026, 1 of 1 active firms rate NXTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NXTC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.